Alembic Pharmaceuticals Ltd
NSE:APLLTD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its 3-Year Average (30.7), the stock would be worth ₹981.67 (28% upside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 23.9 | ₹764.7 |
0%
|
| 3-Year Average | 30.7 | ₹981.67 |
+28%
|
| 5-Year Average | 28.8 | ₹922.9 |
+21%
|
| Industry Average | 30.4 | ₹971.32 |
+27%
|
| Country Average | 28.7 | ₹918.48 |
+20%
|
Forward P/E
Today’s price vs future net income
| Today's Market Cap | Net Income | Forward P/E | ||
|---|---|---|---|---|
|
₹144.7B
|
/ |
Jan 2026
₹6.3B
|
= |
|
|
₹144.7B
|
/ |
Mar 2026
₹6.9B
|
= |
|
|
₹144.7B
|
/ |
Mar 2027
₹8.5B
|
= |
|
|
₹144.7B
|
/ |
Mar 2028
₹10.2B
|
= |
|
Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| IN |
|
Alembic Pharmaceuticals Ltd
NSE:APLLTD
|
149.3B INR | 23.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
825.8B USD | 39.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
548.5B USD | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212.4B GBP | 27.5 | |
| CH |
|
Novartis AG
SIX:NOVN
|
220.1B CHF | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
272.3B USD | 15 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 11.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
150.6B USD | 19.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.3B USD | 16.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 18.9 |
| Median | 28.7 |
| 70th Percentile | 44.4 |
| Max | 877 228.1 |
Other Multiples
Alembic Pharmaceuticals Ltd
Glance View
Alembic Pharmaceuticals Ltd., with roots tracing back over a hundred years, began as a modest tincture and alcohol company in Vadodara, India. Its journey from crafting everyday remedies to becoming a stalwart in the pharmaceutical industry exemplifies ambition intertwined with tradition. Today, Alembic stands as a formidable entity, specializing in the research, development, manufacturing, and sale of active pharmaceutical ingredients (APIs) and generic formulations. The company thrives on a blend of innovation and scalability, strategically advancing its manufacturing capabilities while adhering to stringent quality standards. This commitment has not only bolstered its domestic stronghold but also enabled it to penetrate highly regulated international markets, such as the United States and Europe. The company's revenue model is anchored on an extensive portfolio that addresses therapeutic areas ranging from cardiovascular and anti-diabetics to respiratory and anti-infective products. By leveraging its robust R&D infrastructure, Alembic consistently introduces new and complex generics, amplifying its offerings while navigating the generic drug pricing pressures. Their vertically integrated operations ensure cost efficiency and control over API supplies, easing supply chain constraints and fortifying their competitive position. Additionally, strategic partnerships and investments in advanced manufacturing technologies have augmented its capability to meet global demands, cementing Alembic’s reputation as a reliable partner in the pharmaceutical landscape. This multifaceted approach not only expands its business horizons but firmly establishes Alembic as a key player in addressing global healthcare needs.